General description
INN
Vinblastine
ATC codes
Medicine type
Chemical agent
EML status history
First added in 1984
(TRS
722)
for
Unspecified malignant neoplasms of ill-defined or unspecified sites
Added in 2015
(TRS
994)
for
Hodgkin lymphoma
Added in 2015
(TRS
994)
for
Kaposi sarcoma of unspecified primary site
Added in 2015
(TRS
994)
for
Germ cell tumour of testis
Added in 2015
(TRS
994)
for
Other specified malignant neoplasms of the ovary
Removed in 2015
(TRS
994)
for
Unspecified malignant neoplasms of ill-defined or unspecified sites
Added in 2021
(TRS
1035)
for
Other specified gliomas of brain
Added in 2023
(TRS
1049)
for
Anaplastic large cell lymphoma, ALK-positive
Added in 2023
(TRS
1049)
for
Anaplastic large cell lymphoma, ALK-negative
Added in 2023
(TRS
1049)
for
Langerhans cell histiocytosis
Wikipedia
DrugBank
Recommendations
Section
Cytotoxic medicines
- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)
- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Indications
Hodgkin lymphoma
Kaposi sarcoma of unspecified primary site
Germ cell tumour of testis
Other specified malignant neoplasms of the ovary
Unspecified malignant neoplasms of ill-defined or unspecified sites
Other specified gliomas of brain
Anaplastic large cell lymphoma, ALK-positive
Anaplastic large cell lymphoma, ALK-negative
Langerhans cell histiocytosis